Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib + dabrafenib ± panitumumab in Japanese patients with cancer
jRCT2080222410Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of trametinib, dabrafenib + trametinib and panitumumab in cancer (2 arms), sponsored by Novartis. Started Mar 2014; status: completed.
02
Drugs
trametinibdabrafenib + trametinibpanitumumab
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080222410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222410.